Randomized, controlled trial of conjunctival autografting combined with subconjunctival bevacizumab for primary pterygium treatment: 1-year follow-up

Clinical and Experimental Ophthalmology

Volumn 42, Issue 3, 2014, Pages 235-241

  Nava Castañeda, Angel ^a   Olvera Morales, Osiris ^a   Ramos Castellon, Cynthia ^a   Garnica Hayashi, Lilia ^a   Garfias, Yonathan ^a,b  

^a INSTITUTE OF OPHTHALMOLOGY CONDE DE VALENCIANA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Clinical trial; Conjunctival allograft; Pterygium; Subconjunctival bevacizumab

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; AUTOGRAFT; CLINICAL ARTICLE; CONJUNCTIVAL AUTOGRAFT; CONJUNCTIVITIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; ISCHEMIA; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PTERYGIUM; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE;

CLINICAL TRIAL; CONJUNCTIVAL ALLOGRAFT; PTERYGIUM; SUBCONJUNCTIVAL BEVACIZUMAB;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMBINED MODALITY THERAPY; CONJUNCTIVA; FEMALE; HUMANS; INJECTIONS, INTRAOCULAR; ISCHEMIA; MALE; MIDDLE AGED; PTERYGIUM; RECURRENCE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84899066953     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/ceo.12140     Document Type: Article

References (40)

1. Bradley JC, Yang W, Bradley RH etal. The science of pterygia. Br J Ophthalmol 2010; 94: 815-820.
2. Gallagher MJ, Giannoudis A, Herrington CS, Hiscott P. Human papillomavirus in pterygium. Br J Ophthalmol 2001; 85: 782-784.
3. Garfias Y, Bautista-De Lucio VM, Garcia C etal. Study of the expression of CD30 in pterygia compared to healthy conjunctivas. Mol Vis 2009; 15: 2068-2073.
4. Nolan TM, DiGirolamo N, Sachdev NH etal. The role of ultraviolet irradiation and heparin-binding epidermal growth factor-like growth factor in the pathogenesis of pterygium. Am J Pathol 2003; 162: 567-574.
5. Jin J, Guan M, Sima J etal. Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia. Cornea 2003; 22: 473-477.
6. Di Girolamo N, Wakefield D, Coroneo MT. UVB-mediated induction of cytokines and growth factors in pterygium epithelial cells involves cell surface receptors and intracellular signaling. Invest Ophthalmol Vis Sci 2006; 47: 2430-2437.
7. Golu T, Mogoanta L, Streba CT etal. Pterygium: histological and immunohistochemical aspects. Rom J Morphol Embryol 2011; 52: 153-158.
8. Aspiotis M, Tsanou E, Gorezis S etal. Angiogenesis in pterygium: study of microvessel density, vascular endothelial growth factor, and thrombospondin-1. Eye 2007; 21: 1095-1101.
9. Marcovich AL, Morad Y, Sandbank J etal. Angiogenesis in pterygium: morphometric and immunohistochemical study. Curr Eye Res 2002; 25: 17-22.
10. Kajdaniuk D, Marek B, Borgiel-Marek H, Kos-Kudla B. Vascular endothelial growth factor (VEGF) - part 1: in physiology and pathophysiology. Endokrynol Pol 2011; 62: 444-455.
11. Unemori EN, Ferrara N, Bauer EA, Amento EP. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 1992; 153: 557-562.
12. Magdelaine-Beuzelin C, Pinault C, Paintaud G, Watier H. Therapeutic antibodies in ophthalmology: old is new again. MAbs 2010; 2: 176-180.
13. Gueudry J, Richez F, Tougeron-Brousseau B etal. Subconjunctival bevacizumab for corneal neovascularization. J Fr Ophtalmol 2010; 33: 630-636.
14. Dastjerdi MH, Al-Arfaj KM, Nallasamy N etal. Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol 2009; 127: 381-389.
15. Besharati MR, Manaviat MR, Souzani A. Subconjunctival bevacizumab injection in treatment of pterygium. Acta Med Iran 2011; 49: 179-183.
16. Enkvetchakul O, Thanathanee O, Rangsin R etal. A randomized controlled trial of intralesional bevacizumab injection on primary pterygium: preliminary results. Cornea 2011; 30: 1213-1218.
17. Lekhanont K, Patarakittam T, Thongphiew P etal. Randomized controlled trial of subconjunctival bevacizumab injection in impending recurrent pterygium: a pilot study. Cornea 2012; 2: 155-161.
18. Shenasi A, Mousavi F, Shoa-Ahari S etal. Subconjunctival bevacizumab immediately after excision of primary pterygium: the first clinical trial. Cornea 2011; 30: 1219-1222.
19. Welch MN, Reilly CD, Kalwerisky K etal. Pterygia measurements are more accurate with anterior segment optical coherence tomography - a pilot study. Nepal J Ophthalmol 2011; 3: 9-12.
20. Prabhasawat P, Barton K, Burkett G, Tseng SC. Comparison of conjunctival autografts, amniotic membrane grafts, and primary closure for pterygium excision. Ophthalmology 1997; 104: 974-985.
21. Hosseini H, Nejabat M, Khalili MR. Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia. Med Hypotheses 2007; 69: 925-927.
22. Razeghinejad MR, Hosseini H, Ahmadi F etal. Preliminary results of subconjunctival bevacizumab in primary pterygium excision. Ophthalmic Res 2010; 43: 134-138.
23. Banifatemi M, Razeghinejad MR, Hosseini H, Gholampour A. Bevacizumab and ocular wound healing after primary pterygium excision. J Ocul Pharmacol Ther 2011; 27: 17-21.
24. Galor A, Yoo SH, Piccoli FV etal. Phase I study of subconjunctival ranibizumab in patients with primary pterygium undergoing pterygium surgery. Am J Ophthalmol 2010; 149: 926-931 e922.
25. Bhasin P, Gujar P. A case of recipient bed melt and wound dehiscence after penetrating keratoplasty and subconjunctival injection of bevacizumab. Cornea 2012; 31: 1342-1343.
26. Calcagni M, Althaus MK, Knapik AD etal. In vivo visualization of the origination of skin graft vasculature in a wild-type/GFP crossover model. Microvasc Res 2011; 82: 237-245.
27. Bahar I, Kaiserman I, McAllum P etal. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res 2008; 33: 23-28.
28. You IC, Kang IS, Lee SH, Yoon KC. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization. Acta Ophthalmol 2009; 87: 653-658.
29. Doctor PP, Bhat PV, Foster CS. Subconjunctival bevacizumab for corneal neovascularization. Cornea 2008; 27: 992-995.
30. Wu PC, Kuo HK, Tai MH, Shin SJ. Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium. Cornea 2009; 28: 103-104.
31. D'Ombrain A. The surgical treatment of pterygium. Br J Ophthalmol 1948; 32: 65-71.
32. Hayasaka S, Noda S, Yamamoto Y, Setogawa T. Postoperative instillation of low-dose mitomycin C in the treatment of primary pterygium. Am J Ophthalmol 1988; 106: 715-718.
33. Mahar PS, Nwokora GE. Role of mitomycin C in pterygium surgery. Br J Ophthalmol 1993; 77: 433-435.
34. Singh G. Postoperative instillation of low-dose mitomycin C in the treatment of primary pterygium. Am J Ophthalmol 1989; 107: 570-571.
35. Kenyon KR, Wagoner MD, Hettinger ME. Conjunctival autograft transplantation for advanced and recurrent pterygium. Ophthalmology 1985; 92: 1461-1470.
36. Said A, Fouad AR, Mostafa MS, Abbas S. Surgical management of recurrent pterygium by an operation of transposition. Bull Ophthalmol Soc Egypt 1975; 68: 81-84.
37. Lewallen S. A randomized trial of conjunctival autografting for pterygium in the tropics. Ophthalmology 1989; 96: 1612-1614.
38. Sebban A, Hirst LW. Treatment of pterygia in Queensland. Aust N Z J Ophthalmol 1991; 19: 123-127.
39. Ang LP, Chua JL, Tan DT. Current concepts and techniques in pterygium treatment. Curr Opin Ophthalmol 2007; 18: 308-313.
40. Devereaux PJ, Bhandari M, Clarke M etal. Need for expertise based randomised controlled trials. BMJ 2005; 330: 88-91.